Supplementary Files
Keywords
How to Cite
Abstract
Objective: This study aims to evaluate and compare the effects of suprachoroidal and intravitreal triamcinolone administration, as a primary treatment, on best corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) in patients with diabetic macular edema (DME).
Methods: A quasi-experimental study was conducted from November 2022 to April 2023. 64 eyes were enrolled with Inclusion criteria comprising patients with diabetic macular edema (DME) (central involving) with BCVA < 6/9, CMT > 300 µm on optical coherence tomography (OCT), and no prior DME treatment. Patients were divided into suprachoroidal triamcinolone (SCTA) (Group I) and intravitreal triamcinolone (IVTA) (Group II) groups. Follow-up occurred at 1 week, 1 month, and 3 months post-injection. BCVA, CMT, and IOP were recorded. Data were analyzed using SPSS with a significance threshold of p < 0.05.
Results: Both treatment groups exhibited improved BCVA and reduced CMT. Suprachoroidal delivery demonstrated more substantial visual acuity improvements compared to the intravitreal group. Reduction in IOP was observed in the suprachoroidal group at 1stweek post-treatment (p<0.001), while the intravitreal group experienced increased IOP at later follow-ups (p<0.001).
Conclusion: This study illuminates the efficacy of both suprachoroidal and intravitreal triamcinolone administration as the primary treatment for DME. While both modalities displayed promising outcomes, suprachoroidal delivery exhibited more substantial visual acuity improvements with fewer side effects and promising alternatives for DME treatment.
Keywords: Macular Edema, Intravitreal, Triamcinolone Acetonide, Suprachoroidal, Visual Acuity, Intraocular Pressure.
References
Chan LK, Lin SS, Chan F, Ng DS. Optimizing treatment for diabetic macular edema during cataract surgery. Frontiers in Endocrinology. 2023 Jan 25;14:1106706.DOI:10.3389/fendo.2023.1106706
Zhang J, Zhang J, Zhang C, Zhang J, Gu L, Luo D, Qiu Q. Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications. Cells. 2022 Oct 25;11(21):3362.DOI: 10.3390/cells11213362
Kropp M, Golubnitschaja O, Mazurakova A, Koklesova L, Sargheini N, Vo TTKS, et al. Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications—risks and mitigation. EPMA J. 2023 Mar 1;14(1):21–42.DOI: 10.1007/s13167-023-00314-8
Tomita Y, Lee D, Tsubota K, Negishi K, Kurihara T. Updates on the Current Treatments for Diabetic Retinopathy and the Possibility of Future Oral Therapy. J Clin Med. 2021 Jan;10(20):4666.DOI:10.3390/jcm10204666
Al –Qaysi FA, Awheash AA, Sirwan K. The outcome of Photocoagulation Treatment of Retinal Vascular Diseases. Al-Kitab J Pure Sci. 2023 Jun 25;7(1):1–10. Available from: 10.3389/fendo.2023.1108394
Virgili G, Parravano M, Menchini F, Evans JR. Anti‐vascular endothelial growth factor for diabetic macular oedema. Cochrane Database of Systematic Reviews. 2014.DOI10.1002/14651858.CD007419.pub4/full.
Rittiphairoj T, Mir TA, Li T, Virgili G. Intravitreal steroids for macular edema in diabetes. Cochrane Database of Systematic Reviews. 2020(11).DOI:10.1002/14651858.CD005656.pub3/full.
Wan C rei, Muya L, Kansara V, Ciulla TA. Suprachoroidal Delivery of Small Molecules, Nanoparticles, Gene and Cell Therapies for Ocular Diseases. Pharmaceutics. 2021 Feb;13(2):288.DOI.10.3390/pharmaceutics13020288
Naftali Ben Haim L, Moisseiev E. Drug Delivery via the Suprachoroidal Space for the Treatment of Retinal Diseases. Pharmaceutics. 2021 Jul;13(7):967. DOI: 10.3390/pharmaceutics13070967.
Ateeq A, Majid S, Memon NA, Hayat N, Somroo AQ, Fattah A. Suprachoroidal injection of triamcinolone acetonide for management of resistant diabetic macular oedema. The Journal of the Pakistan Medical Association.2023 Feb 1;73(2):239–44.DOI: 10.47391/JPMA.2239
Tayyab H, Ahmed CN, Sadiq MAA. Efficacy and safety of Suprachoroidal Triamcinolone Acetonide in cases of resistant diabetic Macular Edema. Pakistan journal of medical sciences. 2020;36(2):42–7. DOI: 10.12669/pjms.36.2.1194.
García Layana A, Adán A, Ascaso FJ, Cabrera F, Donate J, Escobar Barranco JJ, et al. Use of intravitreal dexamethasone implants in the treatment of diabetic macular edema: Expert recommendations using a Delphi approach. Eur J Ophthalmol. 2020 Sep 1;30(5):1042–52. DOI: 10.1177/1120672119861623
Steeples LR, Anand N, Moraji J, Jones NP. Clinical Outcomes of Intravitreal Preservative-Free Triamcinolone Preparation (Triesence®) for Cystoid Macular Oedema and Inflammation in Patients with Uveitis. Ocul Immunol Inflamm. 2018 Oct 3;26(7):997–1004. DOI: 10.1080/09273948.2017.1294185
Takamura Y, Shimura M, Katome T, Someya H, Sugimoto M, Hirano T, et al. Effect of intravitreal triamcinolone acetonide injection at the end of vitrectomy for vitreous haemorrhage related to proliferative diabetic retinopathy. British Journal Ophthalmology. 2018 Oct 1;102(10):1351–7. DOI: 10.1136/bjophthalmol-2017-311377
Abdelshafy Tabl A, Tawfik Soliman T, Anany Elsayed M, Abdelshafy Tabl M. A Randomized Trial Comparing Suprachoroidal and Intravitreal Injection of Triamcinolone Acetonide in Refractory Diabetic Macular Edema due to Epiretinal Membrane. Journal Ophthalmology. 2022 Jan 21;2022:e7947710. DOI: 10.1155/2022/7947710
Yeh S, Khurana RN, Shah M, Henry CR, Wang RC, Kissner JM, et al. Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial. Ophthalmology. 2020 Jul 1;127(7):948–55. DOI: 10.1016/j.ophtha.2020.01.006
Zakaria YG, Salman AG, Said AMA, Abdelatif MK. Suprachoroidal versus Intravitreal Triamcinolone Acetonide for the Treatment of Diabetic Macular Edema. Clin Ophthalmol. 2022 Mar 11;16:733–46. DOI: 10.2147/OPTH.S351853
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyright (c) 2023 Fatima Shafqat Khan, Asfandyar Asghar, Brig Rana Intisar-ul-haq , Tehmina Nazir, Naila Obaid , Munazza Aslam